These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33129132)

  • 1. Making legitimacy: Drug user representation in United Nations drug policy settings.
    Madden A; Lancaster K; Ritter A; Treloar C
    Int J Drug Policy; 2021 Jan; 87():103014. PubMed ID: 33129132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transnational social movement theory and the waning war on drugs: Case studies from UNGASS 2016.
    Mostyn B; Gibbon H
    Int J Drug Policy; 2018 Jan; 51():148-155. PubMed ID: 29273560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rethinking 'flexibilities' in the international drug control system-Potential, precedents and models for reforms.
    Collins J
    Int J Drug Policy; 2018 Oct; 60():107-114. PubMed ID: 28129946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "How can anybody be representative for those kind of people?" Forms of patient representation in health research, and why it is always contestable.
    Maguire K; Britten N
    Soc Sci Med; 2017 Jun; 183():62-69. PubMed ID: 28463721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atmospheric pressure: Russian drug policy as a driver for violations of the UN Convention against Torture and the International Covenant on Economic, Social and Cultural Rights.
    Golichenko M; Sarang A
    Health Hum Rights; 2013 Jun; 15(1):E135-43. PubMed ID: 25006082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards revision of the UN drug control conventions: harnessing like-mindedness.
    Bewley-Taylor DR
    Int J Drug Policy; 2013 Jan; 24(1):60-8. PubMed ID: 23036654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (Re)defining legitimacy in Canadian drug assessment policy? Comparing ideas over time.
    Boothe K
    Health Econ Policy Law; 2021 Oct; 16(4):424-439. PubMed ID: 33557999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UNGASS 2016: Insights from Europe on the development of global cannabis policy and the need for reform of the global drug policy regime.
    Chatwin C
    Int J Drug Policy; 2017 Nov; 49():80-85. PubMed ID: 26795703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From a Single Voice to Diversity: Reframing 'Representation' in Patient Engagement.
    Scholz B; Kirk L; Warner T; O'Brien L; Kecskes Z; Mitchell I
    Qual Health Res; 2024 Jan; ():10497323231221674. PubMed ID: 38229426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global drug policy at an impasse: Examining the politics of the 2016 United Nations General Assembly Special Session.
    Sischy J; Blaustein J
    Int J Drug Policy; 2018 Oct; 60():74-81. PubMed ID: 30173003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thinking Politically About UN Political Declarations: A Recipe for Healthier Commitments-Free of Commercial Interests Comment on "Competing Frames in Global Health Governance: An Analysis of Stakeholder Influence on the Political Declaration on Non-communicable Diseases".
    Buse K; Mialon M; Jones A
    Int J Health Policy Manag; 2022 Jul; 11(7):1208-1211. PubMed ID: 34634885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV and human rights in U.N. drug control policy: making inroads, barely.
    Elliott R
    HIV AIDS Policy Law Rev; 2008 Jul; 13(1):40-1. PubMed ID: 18727192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of evidence and the expert in contemporary processes of governance: the case of opioid substitution treatment policy in England.
    Duke K; Thom B
    Int J Drug Policy; 2014 Sep; 25(5):964-71. PubMed ID: 24582381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Making up a new drug user from depenalization to repenalisation of drug users in Denmark.
    Houborg E; Søgaard TF; Mogensen SAI
    Int J Drug Policy; 2020 Jun; 80():102660. PubMed ID: 31980294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Civil society participation in global public private partnerships for health.
    Storeng KT; de Bengy Puyvallée A
    Health Policy Plan; 2018 Oct; 33(8):928-936. PubMed ID: 30165606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engaging people who use drugs in policy and program development: a review of the literature.
    Ti L; Tzemis D; Buxton JA
    Subst Abuse Treat Prev Policy; 2012 Nov; 7():47. PubMed ID: 23176382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legitimacy in the 'secular church' of the United Nations.
    Troy J
    Int Relat (David Davies Mem Inst Int Stud); 2020 Dec; 34(4):565-582. PubMed ID: 33487774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Greenpeace and the online genetically modified food debate in the UK: The role of science and scientific evidence in 'environmental representation'.
    Price C
    Public Underst Sci; 2023 May; 32(4):489-503. PubMed ID: 36519397
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.